$20.08
-1.2%Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Wall Street analysts project that ALMS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 39.33, with estimates ranging from a low of 25.00 to a high of 51.00.
The consensus 1-year price target stands at 39.33, with estimates ranging from a low of 25.00 to a high of 51.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $22.40M worth of ALMS shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
705.9K
12.00M
0
0.00
+12.0M
+$12.00M
1.3M
9.22M
0
0.00
+9.2M
+$9.22M
289.0K
1.18M
0
0.00
+1.2M
+$1.18M
Akkaraju Srinivas
Director
$15.01M
Foresite Labs, Llc
10 Percent Owner
$5.35M
Foresite Capital Management Vi Llc
10 Percent Owner
$533K
Tananbaum James B.
Director, 10 Percent Owner:
$533K
Tetrault Lynn A.
Director
$204K
No selling activity
Strong bullish signal with $22.40M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
Continue your ALMS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.